Amphastar Pharmaceuticals, Inc. (AMPH) Stock

Amphastar Pharmaceuticals, Inc. (AMPH) is a Healthcare stock trading at $18.79 (as of 2026-06-18), with a market capitalization of $798.96M and a trailing P/E of 12.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Valuation — source: SEC EDGAR (first-party)
Price$18.79
Market Cap$798.96M
P/E Ratio12.1
EV / EBITDA8.9
Price / Book1.15
Price / Sales1.23
DCF Value (model)$56.23
DCF Upside vs Price199.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$719.89M
Net Margin13.6%
Return on Equity10.2%
Debt / Equity0.80
Current Ratio3.85
Revenue Growth (YoY)-1.7%
EPS Growth (YoY)-36.2%
FCF Growth (YoY)-29.7%
Financial Health — source: SEC EDGAR
Altman Z-Score2.26 (grey)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Stock P/E12.1
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-42.3%
vs Industry-29.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($106.20M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOYongfeng Zhang
Employees2,028
CountryUS
IPO Date2014-06-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Schrödinger, Inc. (SDGR)
  • Palvella Therapeutics, Inc. (PVLA)
  • Septerna, Inc. (SEPN)
  • Savara Inc. (SVRA)
  • Omeros Corporation (OMER)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Inhibrx Biosciences, Inc. (INBX)
AMPH earnings history · AMPH institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.